

#53166

Date: September 11, 2023

Subject: Adjusted Surface Oncology, Inc. – Determination of Deliverable

Adjusted Option Symbol: CHRS1

Adjusted Surface Oncology, Inc. options were adjusted on September 8, 2023 (See OCC Information Memo #53154). The new deliverable became 1) 100 x a number of Coherus BioSciences, Inc. (CHRS) Common Shares equal to the exchange ratio, calculated as described in the SURF/CHRS Proxy Statement/Prospectus dated July 26, 2023 ("Proxy"), and 2) Cash in lieu of fractional CHRS shares, if any. Settlement of the CHRS and cash components of CHRS1 options exercise/assignment activity were subject to delayed settlement.

OCC has been informed that the final merger consideration is 0.196 CHRS shares with cash paid in lieu of fractional CHRS shares, plus one non-transferable Contingent Value Right ("CVR") per SURF share held.

NOTE: The CVR represents a non-transferable contractual right to receive an additional payment. The adjusted CHRS1 option deliverable will not include the non-transferable CVRs.

OCC has not yet been informed of a price to be used in determining cash in lieu of fractional shares.

Now that the distribution ratio has been determined, OCC will require Put exercisers and Call assignees, during the period of September 8, 2023 through September 11, 2023, to deliver the appropriate number of CHRS shares.

Terms of the CHRS1 options are as follows:

New Deliverable

Per Contract: 1) 19 Coherus BioSciences, Inc. (CHRS) Common Shares

3) Cash in lieu of 0.6 fractional CHRS shares

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price

changes of any security.

Strike Prices: Unchanged

CUSIP: CHRS: 19249H103

Multiplier: 100 (i.e., a premium of 1.50 yields \$150)

Settlement

The CHRS component of CHRS1 exercise/assignment activity, which was delayed on September 8, 2023, will settle through National Security Clearing Corporation (NSCC). OCC will continue to delay the cash portion of the CHRS1 deliverable until the cash in lieu amount is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Pricing

Until the cash in lieu amount is determined, underlying price for CHRS1 options will be determined as follows:

CHRS1 = 0.196 (CHRS)

For example, if CHRS closes at 4.89, the CHRS1 prices would be calculated as follows:

CHRS1 = 0.196 (4.89) = 0.96

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.